Roche and Spark Therapeutics’ road to a US$4.3 billion merger has been a rocky one, with various delays pushing the long-gestating agreement back four times. Now, in order to get all its regulatory ducks in a row, Roche is moving its own deal-close deadline back as well.
Roche moved its Spark closing deadline from January 31, 2020, to April 30, 2020, according to a Monday, July 8, regulatory filing. The move is a precautionary one, meant to give the deal partners time to clear any hurdles that may come up as US and UK antitrust regulators review the companies’ marriage.
In a note to Spark investors, Roche CEO Severin Schwan wrote that the plan was still to close the merger in 2019 despite the new deadline.
Full Content: Biopharma Dive
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
